Bone Biologics Corp.
BBLG.US | Manufacture of pharmaceuticals, medicinal chemical and botanical products
Bone Biologics Corp is an orthobiologics company focused on bone regeneration in spinal fusion using its proprietary recombinant human protein, NELL-1. NELL-1 is a bone growth factor that is intended to enhance bone regeneration in spinal fusion procedures. The company is currently in the pre-clinic...Show More
Better Health for All
10
Bone Biologics Corp's entire business is devoted to developing NELL-1/NB1 for bone regeneration, which has shown exceptional potential health benefits, including a 37.5% increase in fusion rates in preclinical sheep trials.
1
The company has no products with significant negative health impacts, as its sole focus is on a health-positive offering. The company's product is in early clinical stages, with preclinical animal studies showing a strong safety profile and its mechanism of action highlighted for reducing safety risks compared to existing therapies.
2
The company allocated $5 million from a public offering to fund clinical trials and patent expansion.
3
It recently filed a U.S. patent for the NB1 device.
4
The company has received Human Research Ethics Committee (HREC) approval for its pilot clinical trial in Australia, and the study design was reviewed and agreed upon by the U.S. FDA’s Division of Orthopedic Devices.
5
Fair Money & Economic Opportunity
0
No evidence available to assess Bone Biologics Corp on Fair Money & Economic Opportunity.
Fair Pay & Worker Respect
0
No specific, concrete data points were found in the provided articles to assess any of the KPIs under the 'Fair Pay & Worker Respect' value. Information regarding living wage coverage, CEO to median employee pay ratio, collective bargaining, safety incident rates, pay equity, worker engagement, employee turnover, labor law violations, insecure contract share, or health insurance coverage is not available.
Fair Trade & Ethical Sourcing
0
The provided articles, an investor relations document and a press release regarding a clinical trial, do not contain any data relevant to fair trade and ethical sourcing metrics. No information was found regarding fair-trade certifications, audit frequency, forced or child labor incidents, supply chain traceability, remediation speed, ethical clause coverage in supplier contracts, materials risk index, or supplier diversity spend.
1
Honest & Fair Business
0
No specific, concrete data points were provided in the articles to assess Bone Biologics Corp against the defined KPIs for Honest & Fair Business. The company was notified by Nasdaq on April 7, 2025, for non-compliance with the minimum bid price requirement, but regained compliance by June 24, 2025, and this did not result in a fine.
1
A securities class action lawsuit from June 2019 was mentioned, alleging violations and breach of fiduciary duty, but this is outside the three-year window for regulatory fines and is an allegation, not a fine or a specific metric for any other KPI.
2
Kind to Animals
-80
Bone Biologics Corp conducts preclinical animal studies, including using sheep, and allocates funding for animal testing.
1
There is no evidence of the company employing non-animal testing methods for product safety and efficacy, nor is there any mention of an R&D budget allocated to developing animal-free technologies. The company's animal study design was reviewed and agreed upon by the U.S. Food and Drug Administration.
2
No War, No Weapons
0
Bone Biologics Corp's core business is focused on orthobiologics for bone regeneration in spinal fusion using its NELL-1 protein.
1
This medical focus indicates no involvement in defense or arms-related activities, no development or sale of dual-use products, and operations confined to civilian markets. Therefore, all KPIs related to military, defense, or conflict-related activities are scored as 'N/A – not applicable to core operations' or 'no defense business to oversee' based on the company's stated business model. The articles explicitly state that no sustainability data is available for the company,
2
but the company description itself provides sufficient evidence for the 'N/A' tiers.
Planet-Friendly Business
0
No sustainability data is available for Bone Biologics Corp (BBLG.US) in the provided articles.
1
Therefore, no assessment can be made against the Planet-Friendly Business ethical value.
Respect for Cultures & Communities
0
No evidence available to assess Bone Biologics Corp on Respect for Cultures & Communities.
Safe & Smart Tech
-50
Bone Biologics Corp experienced a data breach in April 2025, affecting 47,000 individuals.
1
Following the incident, a third-party security firm was engaged, and the system was restored within one week.
2
The company filed a notice with the U.S. Department of Health and Human Services Office for Civil Rights regarding the breach.
3
Zero Waste & Sustainable Products
0
No evidence available to assess Bone Biologics Corp on Zero Waste & Sustainable Products.